We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » UCB, Novartis To Co-Develop Two Alpha Synuclein Modulators for Parkinson’s
UCB, Novartis To Co-Develop Two Alpha Synuclein Modulators for Parkinson’s
UCB and Novartis have joined forces in what could be a $1.5 billion deal to develop two investigational molecules targeting alpha synuclein, the misfolded protein involved in Parkinson’s disease.